



The Hemodialysis Patient with a Multidrug Resistant Organism

Dr Sreekanth Koduri

Consultant in Renal Medicine Changi General Hospital



Changi General Hospital

Singapore General Hospital







National Dental Centre Singapore



National Neuroscience Institute



Singapore National

Eve Centre





None





- Overview of MDRO infections
- Risk factors for MDRO colonization and infection
- MDRO prevention and control





- 65yrs old, Chinese, Male
- End stage renal disease secondary to diabetic kidney disease
- Past history of diabetes, hypertension, ischemic heart disease and peripheral vascular disease with a previous ray amputation
- Declined pre-emptive AVF creation
- Hemodialysis via tunneled dialysis catheter





- Catheter Related Blood Stream Infections (CRBSI) episodes
 - MSSA bacteremia treated with Cloxacillin followed by cefazolin
 - MRSA bacteremia treated with Vancomycin

Hemodialysis patient with multidrug resistant organism

- MRI foot Osteomyelitis
- Septic shock, vegetation on tricuspid valve
- Demise in Intensive care unit







Multidrug resistant organisms (MDRO)

 Defined as microorganisms, predominantly bacteria, that are resistant to one or more classes of antimicrobial agents

IOM (1998), eds. Harrison, P.F. Lederberg, J. (National academy press, Washington, DC), pp. 8-74

 Inconsistency in the definitions of MDRO



Review on AMR, Antimicrobial resistance: Tackling a crisis for the health and wealth of nations, 2014



Antibiotic resistance trends across OECD countries



ESAC-Net Database and CDDEP



Timeline of antimicrobial development and resistance



Clatworthy et al. Nature Chemical Biology:2007;3:54 1-8

Changi

SingHealth

General Hospital

Time From Antibiotic Approval or Introduction to Detection of Resistance in Clinical Samples



Years From Approval or Introduction to Market to First Clinical Report of Resistance

Marston HD et al JAMA. 2016;316(11):1193–1204



Number of new antimicrobials approved by the United States Food and Drug Administration since 1983



Source: OECD (2015). Antimicrobial resistance in G7 countries and beyond: economic issues, policies and options for action.

Development of new antibiotics

TABLE 4-4. OVERVIEW OF FDA DRUG DEVELOPMENT PROCESS			
Phase	Timeline	Overall probability of success	
Preclinical	1–6 years		
Clinical	6-11 years		
Investigational new drug application			
Phase 1	21.6 months	30%	
Phase 2	25.7 months	14%	
Phase 3	30.5 months	9%	
Approval of new drug application	0.6-2 years	8%	
Phase 4, post-market surveillance	11–14 years		

Source: http://www.fdareview.org/approval_process.shtml





Economist.com



Cause of death in prevalent dialysis population



PEER Report: Dialysis Care & Outcomes in the U.S., 2014 |Hospitalization |



MDRO in dialysis population

- Disproportionately affected by MDROs compared to general population
- Mortality rates due to infections caused by MDRO are 2-5 fold higher

Mortality with VRE bacteremia vs Vancomycin sensitive enterococcus bacteremia

Study	OR (random) 95% Cl	Weight %	OR (random) 95% CI
Bhavnani [20] DiazGranados [23] Garbutt [15] Lautenbach [11] Linden [22] Lodise [19] Lucas [17] Shay [16] Vergis [21]		$\begin{array}{cccccccccccccccccccccccccccccccccccc$	3.34 [1.61, 6.92] 4.96 [1.20, 20.45] 1.74 [0.50, 6.09] 1.61 [0.72, 3.61] 3.47 [1.47, 8.19] 4.00 [1.20, 13.31] 2.07 [0.96, 4.44] 3.30 [0.71, 15.27] 2.10 [1.14, 3.87]
Total (95% CI)	•	100.00	2.52 [1.87, 3.39]

Carlos A. Diaz Granados et al Clinical Infectious Diseases, Volume 41, Issue 3, 1

August 2005, Pages 327–333



Multidrug resistant organisms (MDRO)

- Methicillin-resistant Staphylococcus aureus
- Vancomycin-resistant enterococci
- Multidrug-resistant gram negative bacteria
 - Extended-spectrum beta-lactamase producing gram-negative bacteria (ESBL)
 - Resistant to cephalosporins and most other antimicrobials
 - Carbapenemase producing gram-negative bacteria
 - Only suspectable to Colistins



Multidrug resistant organisms (MDRO)

	MRSA	VRE	MDR – Gram negative
Infective rates – CRBSI Dialysis Surveillance Report: National Healthcare Safety Network (NHSN)— Data Summary for 2006	20% were due to Staph aureus, out of which 51% were MRSA	8.5% were due to Enterococcus species, out of which 22.5% were VRE	25% of BSI are due to gram-negative bacteria 9.7% ESBL isolates and 3.4% CPCRE isolates
Colonization rates	1.4 to 27% David P Calfee Seminars in Dialysis. Vol 26, No 4 2103, 447-456	2.8 -10.8%	Fewer studies One study showed rates of 16%
Colonization to infection	17-35% of MRSA colonized dialysis patients develop subsequent MRSA infection within one year of detection of carriage Lu P et al Nephrol Dial Transplant 23:1659-1665, 2008	23% of VRE-colonized dialysis patients, compared to only 1% of noncolonized dialysis patients, went on to develop VRE infection	No studies



Risk factors for exposure to MDROs

- Hospital exposure
- Dialysis facility exposure
 - Direct patient to patient transmission
 - Environmental transmission
 - Following a 4hr outpatient HD session of fecally-continent VRE positive patients VRE was detected on dialysis chairs in 54%, on HCW gown in 25% and BP cuff on 8% of the dialysis sessions (Grabsch et al 2006)
 - Health care worker to patient transmission
 - HCW nasal MRSA carriage 2.8-11.6%



Prevalence and acquisition of MRSA, VRE and MDR-GNB in an out-patient hemodialysis facility



Aurora Pop-Vicas et al. CJASN 2008;3:752-758



Spread of MDRO from dialysis patients

- USRDS data 2009
 - 2 admissions per year
 - Average length of stay of 12 days
 - 36% has readmission with in 30days
- Higher prevalence of MDRO colonization in the family members of dialysis patients

Adjusted hospital admission rates & days, by modality





Risk factors for colonization and infection

- Antibiotic exposure
- Type of vascular access



Percentage of antibiotics prescribed according to antibiotic classes for adult ambulatory visits, 2007–09

- 10% of the visits resulted in antibiotic prescription (101million)
- 61% broad spectrum antibiotics
- 40million for presumed respiratory infections (2/3 no indication for antibiotics)





Vancomycin Use Among Chronic Haemodialysis Patients

Appropriate	
Empiric therapy for a febrile patient on haemodialysis pending culture/susceptibility data	73(45)
Treatment of β-lactam–resistant organisms	51(31
β-Lactam allergy	5(3)
Surgical prophylaxis in patient with a prosthesis	2(1)
Total	131(80)
Inappropriate	
Continued therapy despite negative cultures for β-lactam–resistant organisms	23(14)
Routine surgical prophylaxis	4(2)
Single positive blood culture for coagulase-negative staphylococci	1(1)
Prophylaxis for indwelling or peripheral intravascular catheters	5(3)
Total	33(20)
Green K, D'Agata E, Am J Kidney Dis 2000	Changi General H

Patients dialyzing with a tunneled or non- tunneled dialysis catheter have a 12-57 times higher rates of vascular access infections, respectively, than those who dialyze with AVF

Access-associated bloodstream infection

Fistula	26	0.2
Graft	31	0.4
Perm. central line	272	3.1
Temp. central line	21	17.8



Klevens RM et al NHSN data summary for 2006. Semin Dial 21: :24-28, 2008

MDRO prevention and control





HD unit - Horizontal Interventions

- "Horizontal" intervention
 - Infection control practices for all patients due to all pathogens
 - Hand hygiene
 - Wear gloves during all patient contact
 - · Clean and disinfect environmental surfaces around the dialysis machine
 - Aseptic technique during care of vascular access devices
 - Preparation of medications away from the patient's machine and only one patient's medications should be administered at a time
 - Current guidelines doesn't mandate segregation of patients in a dialysis facility, as per their carrier status





HD Unit - CDC check lists and audit tools

Checklist: Hemodialysis catheter connection

Wear mask (if required)
Perform hand hygiene
Put on new, clean gloves
Clamp the catheter and remove caps
Scrub catheter hub with antiseptic
Allow hub antiseptic to dry
Connect catheter to blood lines aseptically
Remove gloves
Perform hand hygiene





Checklist: Hemodialysis catheter exit site care

Wear mask (if required) and remove dressing
Perform hand hygiene
Put on new, clean gloves
Apply skin antiseptic
Allow skin antiseptic to dry
Do not contact exit site (after antisepsis)
Apply antimicrobial ointment*
Apply dressing aseptically
Remove gloves
Perform hand hygiene

* Use an ointment that does not interact with catheter material



https://www.cdc.gov/dialysis/prevention-tools/audit-tools.html



Checklist: Dialysis Station Routine Disinfection

This list can be used if there is no visible soil on surfaces at the dialysis station. If visible blood or other soil is present, surfaces must be cleaned prior to disinfection. The proper steps for cleaning and disinfecting surfaces that have visible soil on them are not described herein. Additional or different steps might be warranted in an outbreak situation. Consider gathering necessary supplies¹ prior to Part A.

Part A: Before Beginning Routine Disinfection of the Dialysis Station

Disconnect and takedown used blood tubing and dialyzer from the dialysis machine.

Discard tubing and dialyzers in a leak-proof container².

Check that there is no visible soil or blood on surfaces

Ensure that the priming bucket has been emptied³.

Ensure that the patient has left the dialysis station⁴.

Discard all single-use supplies. Move any reusable supplies to an area where they will

be cleaned and disinfected before being stored or returned to a dialysis station⁵

Remove gloves and perform hand hygiene.

PART B: Routine Disinfection of the Dialysis Station – AFTER patient has left station

Wear clean gloves.

Apply disinfectant⁶ to all surfaces² in the dialysis station using a wiping motion (with friction).

Ensure surfaces are visibly wet with disinfectant. Allow surfaces to air-dry⁸.

Disinfect all surfaces of the emptied priming bucket³. Allow the bucket to air-dry before reconnection or reuse.

Keep used or potentially contaminated items away from the disinfected surfaces.

Remove gloves and perform hand hygiene.

Do not bring patient or clean supplies to station until these steps have been completed.



Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases



PATIENTS. AT THE HE TOF ALL WE DO.

Infection control practices in 34 US hemodialysis facilities





not







HD Unit - Vertical interventions

- "Vertical" intervention focus on prevention of transmission of one or more specific pathogens
- MRSA decolonization
 - Old studies included MSSA rather than MRSA
 - Topical as well as systemic therapy
 - Reduction in nasal carriage and invasive staphylococcal infections
 - Routine use of Mupirocin and chlorhexidine resulted in development of resistant strains
 - Unresolved issue



Vaccination in Hemodialysis patients



Christopher Bond et al, AJKD, Volume 60, Issue 6, 2012, Pages 959-965



Further interventions in dialysis unit

- Education to the staff and patients
- Root cause analysis of all the MDRO bacteremias
- Quality initiatives in the renal unit to reduce infections





<u>QI project to reduce dialysis catheter related BSI –</u> <u>CGH experience</u>

List of PDSAs

PDSA #1 (March 2016): Educate patients & ward nurses during handing over

PDSA #2 (March 2016): Conducted training for NC on dressing change

PDSA #3 (April 2016): 100% dressing change for newly inserted catheter

PDSA #4 (Jun 2016): Quarterly staff competency audit in Renal and Radiography unit

PDSA #5 (Jun 2016): Pilot wards to change dressing at exit site if required

PDSA #6 (Nov 2016): Ordering of Mupirocin nasal cream and Chlorhexidine body wash

PDSA #7 (Dec 2016): Ask 5 Take 5 conducted in Renal & Radiology for doctors and nurses on catheter insertion process

PDSA #8 (Jan2017): Use of Chlorhexidine wipes to reduce bacteremia load on patients

PDSA #9 (Jan2017): Hospital-wide wet dressing change in wards

PDSA #10 (Jul 2017): Renal patients to wear mask when catheter is being manipulated

PDSA #11 (Aug 2017): Use CHG dressing for all renal patients

PDSA #12 (Nov 2017): Standardize guidelines on prevention of Intravascular device related infection Standardize guidelines for guidewire exchange of temporary central venous catheters

Plan-Do-Study-Act Cycle





Achieved CRBSI (MRSA) target rate since Jul 17

Baseline: 0.56 per 1,000 catheter days | Target: 0.28 per 1,000 catheter days | Current: 0.14 per 1,000 catheter days (Jul 17 to Nov 18)





Hospital – Infection control practices

Vertical approaches

- Active surveillance testing to identify asymptomatic carriers
- Contact precautions for patients colonized or infected with specific organisms
- ?Decolonization of patients colonized or infected with specific organisms

Horizontal approaches

- Standard precautions (eg. hand hygiene)
- Universal use of gloves or gloves and gowns
- Environmental cleaning and disinfection
- Antimicrobial stewardship





Hospital: Antibiotic stewardship program



Core elements of antibiotic stewardship. Global Alliance for Infections in Surgery



1. Reduce the need for antibiotics through improved water, sanitation, and immunization

- 2. Improve hospital infection control and antibiotic stewardship
 - 3. Change incentives that encourage antibiotic overuse and misuse to incentives that encourage antibiotic stewardship

Η

- 4. Reduce and eventually phase out subtherapeutic antibiotic use in agriculture
- 5. Educate health professionals, policy makers, and the public on sustainable antibiotic use
- 6. Ensure political commitment to meet the threat of antibiotic resistance

FIGURE 5-1: Six strategies needed in national antibiotic policies



PATIENTS. AT THE HE RT OF ALL WE DO







N



TACKLING ANTIMICROBIAL **RESISTANCE ON TEN FRONTS**



THE STRAITS TIMES



Drugs flushed toilet

1.1



Recommende

'Invisible pandemic': WHO offers global plan to fight superbugs



Our time with **ANTIBIOTICS** is running out.

Antibiotics are in danger of losing their effectiveness due to misuse and overuse, and in many cases they aren't even needed.

Always seek the advice of a healthcare professional before taking antibiotics.



World Health Organization







